194 related articles for article (PubMed ID: 31677358)
1. Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation.
Kulkarni HS; Tsui K; Sunder S; Ganninger A; Tague LK; Witt CA; Byers DE; Trulock EP; Nava R; Puri V; Kreisel D; Mohanakumar T; Gelman AE; Hachem RR
Am J Transplant; 2020 Apr; 20(4):1028-1038. PubMed ID: 31677358
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival.
Bogyó LZ; Török K; Illés Z; Szilvási A; Székely B; Bohács A; Pipek O; Madurka I; Megyesfalvi Z; Rényi-Vámos F; Döme B; Bogos K; Gieszer B; Bakos E
Respir Res; 2024 Jul; 25(1):262. PubMed ID: 38951782
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
4. Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.
Hachem RR; Kamoun M; Budev MM; Askar M; Ahya VN; Lee JC; Levine DJ; Pollack MS; Dhillon GS; Weill D; Schechtman KB; Leard LE; Golden JA; Baxter-Lowe L; Mohanakumar T; Tyan DB; Yusen RD
Am J Transplant; 2018 Sep; 18(9):2285-2294. PubMed ID: 29687961
[TBL] [Abstract][Full Text] [Related]
5. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
Lobo LJ; Aris RM; Schmitz J; Neuringer IP
J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
7. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.
Hachem RR; Yusen RD; Meyers BF; Aloush AA; Mohanakumar T; Patterson GA; Trulock EP
J Heart Lung Transplant; 2010 Sep; 29(9):973-80. PubMed ID: 20558084
[TBL] [Abstract][Full Text] [Related]
8. Eplet Mismatch Load and
Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
[TBL] [Abstract][Full Text] [Related]
9. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
10. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.
Shino MY; Zhang Q; Li N; Derhovanessian A; Ramsey A; Saggar R; Britton IN; Amubieya OO; Lari SM; Hickey M; Reed EF; Noble PW; Stripp BR; Fishbein GA; Lynch JP; Ardehali A; Sayah DM; Weigt SS; Belperio JA
Am J Transplant; 2022 Feb; 22(2):565-573. PubMed ID: 34464505
[TBL] [Abstract][Full Text] [Related]
11. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study.
Sullivan D; Ahn C; Gao A; Lacelle C; Torres F; Bollineni S; Banga A; Mullins J; Mohanka M; Ring S; Wait M; Peltz M; Duddupudi P; Surapaneni D; Kaza V
Clin Transplant; 2018 Jul; 32(7):e13285. PubMed ID: 29774598
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
16. The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death.
Zazueta OE; Preston SE; Moniodis A; Fried S; Kim M; Townsend K; Wood I; Boukedes S; Guleria I; Camp P; El-Chemaly S; Rosas IO; Chandraker A; Milford E; Goldberg HJ
Transplantation; 2017 Sep; 101(9):2207-2212. PubMed ID: 27893614
[TBL] [Abstract][Full Text] [Related]
17. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
[TBL] [Abstract][Full Text] [Related]
18. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism for immune regulation after human lung transplantation.
Mohanakumar T; Sharma M; Bansal S; Ravichandran R; Smith MA; Bremner RM
J Thorac Cardiovasc Surg; 2019 May; 157(5):2096-2106. PubMed ID: 31288367
[TBL] [Abstract][Full Text] [Related]
20. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
